LifeLines For the Southern California Life Science Community
Biocom: Bringing Your Concerns to Policy Makers And Policy Makers to You
What Does Biocom Membership Mean for Me?
Volunteering to Grow and Diversify the STEM Pipeline
DNA in Action: The Next Chapter in San Diegoâ€™s Sequencing Saga
VOLUME 24, ISSUE 2 S u m m e r 2 0 1 5
ONE TEAM. ONE FOCUS.
TENANT REP FOR THE LIFE SCIENCES INDUSTRY
VERENIUM / BASF
218,000 SF / Tenant Representation
70,000 SF / Tenant Representation
60,000 SF / Tenant Representation
Exterior View @ South Facade TORREYANA
San Diego, CA
April 3, 2013
10,000 SF / Tenant Representation
10,900 SF / Tenant Representation
18,000 SF / Tenant Representation
GENZYME / SANOFI
45,000 SF / Sublease Disposition
70,000 SF / Tenant Representation
64,000 SF / Sale Disposition
CA LICENSE NO. 791657
CA LICENSE NO. 1167920
CA LICENSE NO. 1855220
IN THIS ISSUE 2
Cover Story: DNA in Action: The Next Chapter in San Diego’s Sequencing Saga
Biocom Briefly: FDA will miss departing chief -San Diego, too
Public Policy : Bringing Your Concerns to Policy Makers And Policy Makers to You
10 Public Policy : The Consequence of Drought 12 Guest: San Diego Welcomes AdvaMed 2015 14 Membership Update: What Does Biocom Membership Mean for Me?
By Joe Panetta, President and CEO, Biocom
WELCOME TO LIFELINES Welcome to the second edition of LifeLines for 2015, part of our continuing celebration of Biocom’s 20 years of success. We are proud to represent the longestestablished life science association in California and the leading advocacy voice for the Southern California life science community. Frankly, there is no other life science cluster in the world quite like ours, with its
17 Biocom Institute: Volunteering to Grow and
innovative research and technology, collaborative culture, exceptional opportunities for
18 Science Festival: San Diego Festival of Science &
Albert Einstein arrived for his first visit, 85 years ago, he remarked, “I feel that you
20 Members in Action: BIO Over the years, Biocom
of living in which we find harmoniously combined the joy of life and the joy of work.” I
Diversify the STEM Pipeline
Engineering – An Epic Success Golf Tournament
25 Purchasing Group: Biocom Purchasing Group: Reaching New Heights
26 Premium Member Spotlights:
Alexandria, COI Pharmaceuticals, Jones Day, KPMG, Biocom
professional achievement and superior recreational and cultural environment. When are justified in looking into the future with true assurance, because you have a mode think you’ll agree that the same holds true today. Our members work together to make Biocom a harmonious association that helps lead this great life science innovation ecosystem and project our industry’s voice throughout Southern California, Sacramento and Washington, DC. We are especially pleased by Biocom’s global membership growth, with many
30 Biocom Board and Committees 31 Biocom Membership
members from life science clusters in Japan and southern France who want to partner
E D I TO R : Jennifer Landress CO P Y E D I TO R : Josh Baxt DESIGN & LAYOUT: Arlene Arreola
success and guide our community into an even more prominent global role.
with our Southern California members. Our board and senior management team are completing a bold new strategic plan, which will help Biocom accelerate life science In keeping with the leadership theme, our cover story focuses on the next chapter in our region’s sequencing saga. A mere decade after the first commercial roll-out of a next generation sequencing instrument, Southern California has emerged as a hotbed for genomics. We are putting petabytes of genetic data to work to more efficiently
VOLUME 24, ISSUE 2
develop new diagnostics and therapeutics. In advocacy, the most pressing issue is at home. We discuss how Biocom is working with elected officials to address our members’ concerns about California’s ongoing, severe drought. In addition, you will read about our recent Biocom town hall meetings and roundtables with NIH director Dr. Francis Collins, FDA/CDRH director Dr. Jeffrey Shuren, House Democratic Whip Steny Hoyer and Reps. Scott Peters and Xavier Becerra.
Biocom, a member driven organization, is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development.
The remainder of this issue is filled with interesting stories about what Biocom membership means for individual employees, our improved Office Depot Purchasing Group contract and how our Biocom Institute helps companies give back to the community. We review our successful Festival of Science & Engineering while previewing the first-ever AdvaMed Annual Convention in San Diego, which Biocom will cohost this October. The Biocom team and our board continue to work hard to ensure that we remain the leading life science association in California, with a focus on accelerating our membership’s success. Please enjoy this issue of Lifelines, and I hope you’ll stay in touch with us at Biocom’s beautiful new life science community headquarters on Torrey Pines Mesa.
WWW.BIOCOM.ORG Biocom LifeLines Spring 2015
By Kelly Quigley
DNA in Action: The Next Chapter in San Diego’s Sequencing Saga
A mere decade after the first commercial rollout of a next-generation sequencing instrument, San Diego has emerged as a hotbed for companies taking the next step—turning reams of genomic data into treatments and cures. By 2025, people all over the world will have their full genome sequenced within hours of birth. This information will serve as a fundamental piece of their electronic medical record and a baseline against all future sequencings—procedures that will be as ordinary as a cholesterol check. That’s the prediction of Gavin Stone, who leads corporate development and marketing at fast-growing Edico Genome. “In 10 years’ time, our reality will be extremely precise, extremely personalized medicine,” Stone says. “Everyone will have their genome and microbiome sequenced on a regular basis and get results back in a matter of minutes, probably while they’re still at the doctor’s office.” If doctors spot any DNA sequence variations that might indicate disease, they can respond swiftly with the right treatment. Edico Genome, which is settling into its new Torrey Pines offices after recently graduating from San Diego’s EvoNexus technology incubator, has created a faster and more affordable method for interpreting the vast quantity of data produced by today’s next-
Biocom LifeLines Summer 2015
generation sequencing machines. The company recently entered into a partnership with Intel Corp. to speed up the process even more, potentially enabling real-time genome analysis. After all, Stone notes, what’s the use of detailed genomic data if researchers or clinicians can’t make sense of it quickly? Edico Genome is one of more than a dozen biotech companies throughout Southern California that are finding new ways to translate DNA data into actionable healthcare information. It’s a mission that extends all the way to the White House, where President Obama spoke out earlier this year against one-size-fitsall medicine and announced funding for genetic-based cancer research as part of a precision medicine initiative. San Diego—with its unique ecosystem of biotech innovators, DNA sequencing giants and computing expertise—is already pushing the boundaries of what’s possible with personalized healthcare. And it’s doing so on many fronts, from Illumina’s development of the first FDA-approved next-gen sequencing system for clinical labs, to a wide variety of molecular diagnostic and bioinformatics
COVER STORY healthcare venture capital firm Domain Associates, also based in San Diego. “Just over a decade ago, it cost $3 billion to sequence one human genome,” she says, referring to the price tag of the Human Grappling with Gigabases Genome Project, completed in 2003. “The second one was $100 Given the flurry of action in clinical genomics, it’s hard to believe million. At those prices, you can’t really understand the basis of that just one decade ago the first next-gen sequencing machine disease. You can maybe look at one or two genomes, but not a was about to hit the market. thousand genomes of people who have a particular type of cancer The Genome Sequencer 20 System arrived first—a product from and compare those to a thousand genomes of healthy people.” 454 Life Sciences, now a division of Roche. Months later came Today, as the $1,000 genome becomes a reality (Illumina Solexa’s game-changing Genome Analyzer, which promoted its declared success on this front in 2014 ability to sequence 1 gigabase of data in a with the launch of its HiSeqX Ten system), single run. At the time, such a claim was genomic data can more easily move from nearly unbelievable. the discovery bench to the patient’s San Diego-based Illumina acquired bedside. Solexa in 2007 and went on to lead the And the economics factor doesn’t global sequencing market—with data just stop at the cost of sequencing a output more than doubling each year, genome. One of the main market drivers exceeding Moore’s law. Today, Illumina’s for personalized medicine is the need to most powerful system, geared towards lower overall medical costs. Quality of population-scale sequencing, produces up patient outcomes is at the forefront, too, to 1,800 gigabases of data in a run. --ADAM SIMPSON, PRESIDENT & COO, CYPHER but it all boils down to delivering care as That’s a whole lot of data to deal with. GENOMICS efficiently—and affordably—as possible. But too much data is rarely a bad thing, “It’s really getting at a fundamental issue says Adam Simpson, president and chief that we have in healthcare,” Kamdar says. operating officer of San Diego-based Cypher Genomics, which Genomic-based medicine offers a clear benefit in its ability to provides human genome sequencing interpretation software and a detect disease earlier and direct people to the best therapies right biomarker discovery service. off the bat. “It’s really a thrilling problem to have,” Simpson says. “You have “The economic benefits of genomics are clear,” adds Simpson 3.2 billion base pairs of information in your body. Now the question of Cypher Genomics. becomes: How do you utilize this information so it becomes However, Simpson notes, before the full economic benefits can useful for clinical diagnostic laboratories and pharmaceutical be realized, U.S. health insurance companies must do a better companies?” job of embracing genomics as a standard element of patient care. Cypher Genomics recently joined forces with San Diego-based molecular diagnostics company Sequenom to develop noninvasive Big Data from Small Samples prenatal tests that pinpoint chromosomal abnormalities usually not Biotech players in San Diego are enabling precision medicine detectable until after birth. The company is also working with drug in many different ways. While companies like Edico Genome and companies to identify disease biomarkers hidden in sequencing Cypher Genomics are focused on how to alleviate the bottleneck of data. The goal is to foster new diagnostics and targeted therapies genomic data, others are working to find more effective and less on a rapid timeline, bringing precision medicine to life. intrusive methods for gathering actionable DNA from patients. “Even two years ago, the conversation was still about the price For example, rather than relying solely on DNA from the initial and analytical validity of sequencing,” Simpson says. “Today, you tissue biopsy to direct cancer treatment, companies are using can safely assume that you’ll have an affordable and completely their technology to track disease progression and drug response by accurate genomic sequence. The conversation is now about clinical capturing microscopic particles of tumor DNA from blood or urine. application.” “Once the sequencer has revealed that a patient has a mutation, you know you want to use a certain drug. But now our interest turns Beyond the $1,000 Genome to tracking how the mutation changes. We want to know when The fact that a clinically focused conversation can even exist that cancer comes back before an imaging study shows metastasis today is rooted in economics, says Kim Kamdar, partner with companies that are helping physicians detect and treat disease earlier than ever before.
“TODAY, YOU C AN SAFELY ASSUME THAT YOU’LL HAVE AN AFFORDABLE AND COMPLETELY ACCURATE GENOMIC SEQUENCE. THE CONVERSATION IS NOW ABOUT CLINIC AL APPLIC ATION.”
Continued Pg 5
Biocom LifeLines Spring 2015
Experience How Everything We Do Has A Single Focus - Your Success
Focusing on private companies preparing to go public or be acquired, we provide aaest and tax services to a wide variety of public companies, early-stage and growing private companies. We are one of San Diegoâ€™s largest Life Sciences and Technology Praccces.
COVER STORY everywhere,” says Antonius Schuh, CEO of Trovagene, which offers noninvasive tests to detect and monitor various cancer mutations. Trovagene’s technology extracts tumor DNA from urine samples and analyzes it using Illumina’s next-gen sequencing equipment. Results reveal whether the tumor is shrinking or if resistant mutations have emerged. With this information, doctors can modify the course of treatment at great speed. And because urine samples can be obtained so easily, patients’ progress can be tracked completely noninvasively on even a daily basis. “I want to know in real-time whether this new drug is resulting in accelerated cancer-cell death,” Schuh says. “I can do this from urine in a very powerful manner, observing a spike in genetic material that results from dying cancer cells.” In April, Dr. Hatim Husain, of the UCSD Moores Cancer Center, presented data from a clinical study showing that Trovagene’s urine-based Precision Cancer Monitoring platform detected the emergence of a rare resistance mutation in metastatic lung cancer patients with greater sensitivity than a tissue biopsy—and months before it could have been detected with imaging equipment. Trovagene’s tests focus on mutations that are known to play a role in cancer and for which targeted therapies are available. As more biomarkers are discovered and drugs developed, Schuh notes, the potential for testing expands. A few miles north of Trovagene, Epic Sciences is likewise developing highly sensitive diagnostics tests that detect and track disease noninvasively. Epic has more than 30 different cancer-focused assays that work on patient blood samples. The company’s “no cell left behind,” technology captures whole cancer cells circulating in blood—cells that were nearly impossible to detect before. The company then genetically profiles the cells to provide insights into disease status. In addition to helping guide treatment, Epic’s analyses also inform the development of new pharmaceuticals and companion diagnostics. Epic CEO Murali Prahalad was formerly a vice president at Carlsbad-based sequencing behemoth Life Technologies, which is now a brand of Thermo Fisher Scientific. And before that, he worked for Sequenom. Such talent crossover occurs throughout the San Diego sequencing scene and is what makes the area such a stronghold for innovation in the genomics space, Kamdar says. “If you just look at Illumina and Life, the two main players in the sequencing space, and you look at the talent they’ve spawned, you see there’s a large group of people in San Diego who have been
quietly and confidently amassing the type of information needed to bring genomics to the clinic,” she says. Factor in San Diego’s dominance in biological research, mobile health, computing (notably, Qualcomm) and the bold presence of people like genomic industry trailblazer J. Craig Venter, and it’s easy to understand why San Diego is leading the way. Speaking of Venter, one of his most recent business ventures—Human Longevity Inc. (HLI) in San Diego—is a genomics and cell therapy-based diagnostic and drug company that’s operating squarely in the precision medicine space. The company is building the largest human genotype and phenotype database in the world, with the ambitious goal of extending the high-performance lifespan and changing the face of aging. “We envisioned a new era in medicine when we founded HLI, in which millions of lives will be improved through genomics and comprehensive phenotype data,” Venter said in a statement his company released earlier this year when he participated in the White House precision medicine event. The company’s comprehensive database is already in place, with thousands of complete human genomes, microbiomes and phenotypic information together with accompanying clinical records. The data is enabling the pharmaceutical industry, academics, physicians and patients to advance understanding of disease and wellness and to apply the knowledge to personalized care.
GIVEN THAT FIVE YEARS AGO HARDLY ANYONE FORESAW THE SPEED AT WHICH GENOMES WOULD BE SEQUENCED TODAY—OR THE PLETHORA OF POTENTIAL CLINIC AL APPLIC ATIONS UNDERWAY—IS IT EVEN POSSIBLE TO PREDICT HOW THE CLINIC AL GENOMICS SCENE WILL LOOK IN FIVE OR 10 YEARS?
Coming Soon: Faster, Cheaper, Better Given that five years ago hardly anyone foresaw the speed at which genomes would be sequenced today—or the plethora of potential clinical applications underway—is it even possible to predict how the clinical genomics scene will look in five or 10 years? Probably not with anything close to 100 percent accuracy, but there are some things most industry leaders agree upon. First, sequencing will continue to get faster and less expensive, and it will be possible on increasingly compact instruments. Meaningful analysis of genomic data for translation to clinical application also will accelerate. Information will deepen as more biomarkers are discovered—and biomarker discovery will surge as more people get sequenced. “To figure out cancer, we need to sequence hundreds of thousands of cancer genomes,” Illumina CEO Jay Flatley has said. Noninvasive diagnostics, such as those from Epic Sciences and Trovagene, will benefit from advances in biomarker discovery and Continued Pg 6
Biocom LifeLines Spring 2015
COVER STORY will be able to provide increasingly real-time disease profiling for even more conditions. And pharma stands to gain too, with more therapies developed to address newly discovered mutations. In addition, the industry will find new ways to elicit healthrelevant knowledge from DNA, as San Diego’s BioNano Genomics already is doing with its whole-genome mapping and structural variation technology. “You will reach a point in the next 10 years where the sheer ability to detect and measure will become a commodity aspect,” Schuh predicts. “In sequencing, the value will continue to shift from the sheer collection of the data to the solutions that integrate clinical practice. It boils down to how we bring this to the patient.” Edico Genome’s Stone guesses that the next wave of innovation, after widespread clinical adoption of genomic medicine, will be a surge in consumer applications—bringing sequencing technologies into a home environment. On the government and policy front, he predicts that within 10 years (but hopefully sooner) payers and healthcare systems will have worked out the data privacy and reimbursement issues that are currently in debate. The industry also will have come together to agree on sequencing standards and protocols—something that’s just starting to happen
now. Illumina joined with four major cancer centers earlier this year to form the Actionable Genome Consortium, which provides guideless to helps oncologists diagnose, classify and treat cancer. And in May, the U.S. National Institute of Standards and Technology made available “reference” DNA that gives labs a unified way to check if their sequencing machines and software are properly analyzing genomes. In another decade, there’s no question that precision medicine will be flourishing. While surely there will be room for improvement, healthcare will be significantly more precise than it is today and genomics will play a much larger role. And in San Diego, which gave birth to today’s thriving sequencing scene, the biotech community will be hard at work on the next big thing. Kelly Quigley is content director at Canale Communications and a former biotech journalist. At Canale, she specializes in thought leadership strategy and content development for life science companies.
Science that spans the spectrum of healthcare Use the same innovative molecular technologies in your drug discovery that are trusted in clinical diagnostics.
MagNA Pure 96 Instrument
LightCycler® 480 Instrument
cobas® 4800 System
For life science research only. Not for use in diagnostic procedures.
For more information, visit http://lifescience.roche.com or contact your Roche representative. LIGHTCYCLER, MAGNAPURE, and COBAS are trademarks of Roche. © 2015 Roche 408-61332-0515
By Joe Panetta, President & CEO, Biocom
FDA will miss departing chief -- San Diego, too Last month, Dr. Margaret Hamburg announced her impending resignation at the end of this month as commissioner of the U.S. Food and Drug Administration after leading the agency for nearly six years. She will step down leaving a legacy of a significantly improved track record for novel drug approvals while at the same time having successfully increased public confidence in drug safety. When Hamburg began her tenure at FDA, she was faced with low morale among staff as a result of continued scandals and congressional scrutiny over such issues as contaminated food and drugs being imported from China and undisclosed side effects of several widely used medicines. She also came in at a time when funding for life science innovation was threatened by the growing economic crisis. Dr. Hamburg began her relationship with Biocom soon after she arrived at the FDA, her interest focused upon a survey that we have conducted periodically over the last 16 years in partnership with PricewaterhouseCoopers (PWC) titled “Improving America’s Health V: A Study of the Working Relationship Between the Life Sciences Industry and FDA.” In 2010, shortly after Dr. Hamburg took over at FDA, Biocom and PWC issued our fifth edition of the survey, which identified numerous challenges facing the FDA under the new health care law, including the mandate to establish a review pathway for biosimilar drugs and a profound lag in the FDA’s ability to keep pace with the rapidly evolving scientific and technical advances in drug and device technology. To her credit, the new commissioner brought Biocom and PWC to the FDA to further explore with her team how the FDA could effectively respond to our findings; we believe the current iteration of the survey, released in February, is an indication of the commissioner’s success over the last five years with more than 75 percent of industry executives indicating that the FDA has improved the quality of its communication and more than 70 percent indicating that feedback and guidance on new regulations had also improved substantially. While the San Diego life science community gives the commissioner solid marks for the progress that has been made during her tenure, the FDA faces profound new challenges in the future, including meeting congressional priorities to approve more so-called “breakthrough therapeutics” under the 21st Century Cures Act, a new Precision Medicine Initiative announced by the president in his State of the Union address, as well as increased consumer and payer focus on cost-effectiveness and improved
Biocom LifeLines Summer 2015
outcomes. All of these issues will have a profound impact on the success of the San Diego life science community in the future in which the primary focus is on these types of products. The new FDA commissioner will have to face pressure to better meet the new demands for approval of innovative products with greater flexibility and more of a need to demonstrate value. Our recent survey concluded relatively few consumers believe that the FDA incorporates their views in the review process; it will be essential that the new commissioner address these concerns as it will also impact our industry’s ability to demonstrate value over currently available therapies. With increased consumer access to medical information including personal health care records and individual genetic sequencing data, consumers are assuming responsibility for information that will without a doubt place greater pressure on the FDA to coordinate and collaborate more with patients. Additionally, the future success of the FDA will be dependent upon the ability of a new commissioner to meet expanding responsibilities to address groundbreaking legislation while taking leadership of regulation within an ever-expanding global marketplace for health care products. San Diego’s life science community is at the epicenter of the development of breakthrough therapies and personalized medicine technologies, with a rapidly growing consumer-focused wireless health sector resulting from the convergence of long-established telecommunications and medical device industries. Our future, and the future of the patients for whom these products are being developed, will lie in large part with the appointment of effective new leadership to not only follow on the path that Commissioner Hamburg has created, but to provide bold new leadership as well.
This Opinion piece originally ran in the U-T San Diego on March 20, 2015.
By Jimmy Jackson, Senior Vice President of Public Policy, Biocom
Biocom: Bringing Your Concerns to Policy Makers And Policy Makers to You We are halfway through 2015, and although it’s already been quite a year, the road ahead is filled with challenges and opportunities. The question we are getting most from our members, elected officials and the media is: How will California’s ongoing drought affect the life science industry? To be honest, no one knows. Biocom is in regular contact with the stakeholders most affected by this crisis, including agencies who supply Southern California’s water. They have repeatedly stated that California can achieve the Governor’s 25 percent water reduction mandate by curtailing ornamental and outdoor water use, including lawns, landscaping and water features. But every Californian must help. If we cannot achieve the 25 percent reduction by limiting these cosmetic uses, then it becomes more likely we will have mandatory shutoffs, which will affect California’s economic drivers, including the life sciences. We will keep our members apprised of the latest developments, including local regulations to decrease water use. In March, Biocom was honored to co-host (with the California Healthcare Institute) a town hall meeting at UCSD with NIH director Francis Collins, who also paid a visit to Biocom member company Organovo. Dr. Collins was excited by the groundbreaking innovation at Southern California companies, and how that is accelerating discoveries and solutions. In April, FDA CDRH director Jeff Shuren visited our members via Skype for a lively and candid session at our quarterly member breakfast. We were also proud to host Congressmen Scott Peters, Steny Hoyer and Xavier Becerra for legislative roundtables. Bringing important decision-makers to our members is an important part of what we do. Biocom’s Washington DC office continues to engage the government on a number of fronts. The two biggest priorities have been educating members of Congress on the potential effects of different patent reform bills and providing input as Congress continues to develop its 21st Century Cures legislation. Some of these patent proposals could have devastating effects on the life science industry, particularly for small companies who may find it harder to protect their intellectual property. On the other hand, 21st Century Cures could be an opportunity to modify and streamline systems so new therapies, cures and devices can get to patients faster. You can read the comments Biocom has offered on these issues in the federal policy section of the Biocom website. At the state level, exciting legislation introduced by San Diego’s
own Speaker of the Assembly Toni Atkins has been gaining ground. This legislation would allow monetization of accrued R&D tax credits for small companies, something Biocom has long sought in the state policy arena. Now that Speaker Atkins has put her considerable influence behind getting these provisions into law, we hope she will make the difference. Earlier this year, Biocom, PhRMA, BIO, CHI several patient groups and many individual companies combined to help stall an onerous state bill (AB 563), which would have required itemized disclosure of all costs associated with bringing any individual drug (costing $10,000 per therapeutic course) to market. The bill will be considered again in January, 2016, if not sooner through a different vehicle. This legislation is part of a nationwide effort by health plans to blame the rising cost of healthcare squarely at the feet of the drug industry, even though data indicates prescription drug spending as a percentage of the health care dollar has not risen in decades. This organized and well-funded campaign of distortion is being met head-on by the industry, but continues to gain traction. The Biocom Public Policy department continues to be your voice to decision-makers. We encourage you to watch the BCQ for the most current news in the policy arena and how it will affect your company.
Jimmy Jackson is the Senior Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.
Biocom LifeLines Spring 2015
By Melanie Nally, Associate Director of Local Government & Regulatroy Affairs, Biocom
The Consequences of Drought It’s 1991 and California is in the midst of a significant drought. The San Diego City Council proposes shutting off water to all manufacturers for two to three hours per day to conserve precious water – not realizing the effect shutoffs will have on the local life science industry. A number of CEOs meet to discuss the issue and decide water shutoffs would cripple their companies. Several approach the San Diego City Council, giving them an overview of the industry and explaining why water can’t be shut off to their businesses. As a result of these efforts, the city initiates the Guaranteed Water for Industry Program, which secures water access for companies, up to drought level two, provided they implement water saving measures. March Miracle rains come and shutoffs are no longer necessary. However, industry and service providers decide they have further interests to pursue together and Biocom is born. Flash forward to 2015. California is again experiencing an historic drought: a fourth dry year with no relief in sight. April marked the first time in 75 years there was no snow at 6,800 feet in the Sierra Nevada Mountains. Overall, the snowpack was 5 percent of its historical average, 28.3 inches. On May 5, the State Water Resources Control Board approved the first mandatory water conservation rules in state history. Effective June 1, all cities and water districts must achieve mandatory reductions between 8 and 36 percent (based on per capita water use) of their 2013 baseline. Governor Brown has said he will support legislation authorizing fines of up to $10,000 per day for cities and districts that don’t meet these targets. These rules stem from the Governor’s April 1 executive order, directing the state water board to reduce potable water usage by 25 percent statewide. The final target for the City of San Diego is 16 percent. In addition, the City of Oceanside must reduce water consumption by 20 percent, the Carlsbad Municipal Water District by 28 percent and the City of Poway by 32 percent. Local water agencies have enacted various restrictions to achieve these goals, including cutting back outdoor irrigation, limiting water service in restaurants and hotels and using recycled water where possible. Regulators say saving urban water is the cheapest and most effective way to ensure communities have enough and avert more drastic cuts. In December, San Diego received 3.5 inches of rain, which led to a 29% reduction in water use. Because of this, we are confident that the 25% statewide reduction target can be achieved solely
Biocom LifeLines Summer 2015
through limiting outdoor irrigation, which accounts for 44% of water use in California. However, if targets cannot be reached through outdoor restriction alone, we anticipate regulators will consider shut off periods. Given that we believe legislators and water regulators understand the importance of the life science industry to the state, we hope they will consider all other avenues before implementing shut off periods. Biocom was founded 20 years ago to educate local officials about water access. Our members depend on a reliable, constant source of water for everyday business. Interrupting these supplies could mean millions of dollars lost in delicate research and production. Biotech and pharmaceutical companies have long been leaders in adopting water saving technologies, such as water recapture and recirculation systems for water intensive machinery. Biocom has supported a number of practical ways to diversify the region’s water supply, such as potable reuse and desalination, and has worked closely with local and state water officials to communicate the industry’s importance to the regional economy. With luck, a developing El Niño will ease the crisis. But regardless, Biocom will be working closely with all stakeholders to help maintain a steady water supply for Southern California’s life science industry.
Melanie Nally is the Associate Director of Local Government and Regulatory Affairs and also heads our facilities and EHS committees.
TRANSFORMING REAL ESTATE INTO REAL
ADVANTAGE For every client, advantage is delivering the broadest, deepest reach and resources any real estate company offers. Transforming property into prosperity, square feet into strong portfolios, scale into global strength. All in service of exceptional outcomes that build real business advantage. Let us put our actionable perspectives, global reach and powerful connections to work for your business.
Build on Advantage
By Ray Briscuso, Managing Partner, AdvaMed 2015: The MedTech Conference
San Diego Welcomes AdvaMed 2015 The medical technology industry is constantly innovating, developing new products and procedures that enhance and save lives around the world. Each year, the Advanced Medical Technology Association hosts the largest gathering of medtech companies and investors at AdvaMed 2015: The MedTech Conference. Here, industry leaders meet for strategic business development, high-level networking and world-class education. Now in its ninth year, AdvaMed 2015 will be held for the first time in San Diego, October 5-7. The 2015 conference will offer enhanced business development programming—providing better opportunities for early and emerging growth companies, as well as investors and business development executives. Early-Stage and Emerging Growth Opportunities AdvaMed 2015 seeks to foster growth among start-up companies developing new, life-saving and life-enhancing devices, diagnostics and digital health technologies. The conference will provide an array of programming for these innovators, including: •
• • •
Emerging & Early Growth Company Issues Panels – Learn from industry leaders, policymakers and peers about the latest trends, challenges and opportunities facing the industry. Entrepreneurship Boot Camp – Learn how to develop an actionable strategic plan. Innovation Showcase – Startups pitch technologies to investors and consolidators. MedTech Partnering – A one-to-one meeting solution designed to maximize networking opportunities for medtech companies and other industry stakeholders
Business Development & Investors AdvaMed 2015 offers exclusive programming and a unique environment for senior business development executives and investors from across the industry to connect and explore opportunities for strategic partnerships and investment. • •
Innovation Showcase & MedTech Innovator – Discover the latest medical technologies and innovations. Business Development & Finance Panel Sessions – Gain insights into the key issues driving medtech investment and deals. MedTech Investor Forum and Business Development Roundtable (invitation only) – Prominent health care investors and top medtech business development executives will come together to share ideas and discuss trends in the marketplace. Strategic Investor Speed Dating (invitation only) – Active health care investors and leading corporate business development teams will be paired for brief one-on-one meetings with promising early-stage medtech companies in the Innovation Showcase.
Biocom LifeLines Summer 2015
Investor – Business Development Reception (invitation-only) – MedTech investors, strategic business development executives and small company innovators will gather for networking immediately preceding the conference’s opening reception.
By the Numbers In 2014, The MedTech Conference welcomed more than 2,300 attendees from 29 countries. Twenty-three of the top 25 medical device companies bring representatives from across their organizations. From c-suite to management, the conference attracts leaders of all levels. Last year, 24 percent of attendees were at the c-suite or president level; 21 percent were vice presidents; 19 percent were executive directors and directors; six percent were partners; and the remaining 30 percent included managing partners, managers, general counsels and others. Nearly 400 business development, investment and finance executives attended AdvaMed 2014, including representatives from these companies: Business Development Abbott Laboratories B. Braun Medical, Inc. Baxter International, Inc. Bayer HealthCare, LLC BD C. R. Bard, Inc. Cardinal Health CareFusion Corporation Covidien Danaher Corporation Edwards Lifesciences Corporation Flextronics Medical GE Healthcare Hill-Rom Hollister Incorporated Hospira Integra Life Sciences Intuitive Surgical Johnson & Johnson Medtronic, Inc. Owens & Minor Philips Healthcare Quidel Sorin S.p.A. St. Jude Medical Stryker Corporation Terumo Corporation Thermo Fisher Scientific ZOLL Medical Finance and Investment
Abbott Ventures Ampersand Capital Partners Arboretum Ventures Ascension Ventures Athena Investment Group Baird Capital Baxter Ventures Deloitte Corporate Finance LLC International Finance Corporation JVC Investment Partners Lightstone Ventures Linden Capital Partners LionBird Ventures Mass Medical Angels Moelis & Company Morgan Stanley OrbiMed Advisors Piper Jaffray Pritzker Group PTV Healthcare Capital RCT Ventures River Cities Capital Funds RoundTable Healthcare Partners Thomas, McNerney & Partners Versant Ventures Water Street Healthcare Partners William Blair
Other Programming: • 30+ Educational Panels • 4 Plenary Sessions • 30+ Industry CEO Speakers • 4 Networking Receptions • 120+ Exhibitors • 40 Innovation Showcase Companies
We look forward to collaborating with Biocom to make this conference a success. Register today and we will see you in October.
Ray Briscuso is Managing Partner for Advamed 2015: The MedTech Conference
Make Your Mark
Professional Science Master’s The Professional Science Master’s in Biotechnology from CSUSM is a degree that leads to jobs with graduates reporting a 97% employment rate at time of graduation. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.
For more information contact us at www.csusm.edu/el/psmlifelines
HURRY! Fall 2014 Start
By Sonali Vittachi, Sales Support Coordinator, Biocom
What Does Biocom Membership Mean for Me? Here’s a common question: My company is a Biocom member; does that mean I am, too? I’m pleased to say yes, that’s exactly what it means. We have worked hard for 20 years to expand our membership benefits, encouraging personal and professional development while saving you money. Biocom Member Employee Resource Guide Here’s a taste of your Biocom benefits.
Get Involved If you’re interested in sharing your life science industry knowledge, discussing current trends or growing your professional network, join a committee. If you don’t have enough time, come to some of our 75 educational and networking events. We believe that bringing people together to learn and socialize is a great way to inspire each other, while keeping our community vibrant and strong.
We’ve got you! Your company is a Biocom member and guess what? You are too! We have lots of perks for your company but did you know that we have something for You Too? Looking for some discounted SeaWorld tickets? Want to take a professional development class? How about a chance to network with other profesSionals?
We can deliver directly to your email
Check out our pages/wall/feed for the scoop on upcoming events, member news, and more.
Sign up for our bi-monthly electronic newsletter and our Upcoming Events newsletter at www.biocom.org.
CommitteeS We know that you want to! If you’re interested in sharing your knowledge of the industry with our life science professionals, discussing current trends or growing your network, then join a committee today.
CONCIERGE Looking for a particular service? With an all-inclusive network of our members’ services, ranging from travel to photography to professional development, Biocom Concierge is your one-stop-shop. www.biocomconcierge.org
CLASSES Thirsty for more knowledge? Want to improve your corporate value? We have courses to invigorate the pep in your step and bring your skills to the next level. Whether you need help with public speaking, presenting, leadership or understanding science lingo, we have what you need.
We Care About You AND Your Family Your family matters to you, so they’re important to us, too. With discounts to SeaWorld, Knott’s Berry Farm, Hyatt Hotels and National Car Rental, to name a few, we offer something for everyone.
Biocom’s life science newsletter
you are Biocom. Get involved. Save money. network.
Making Your Life Better and Easier We’re trying to remove barriers so you can focus on the things you love, both inside and outside of work. We’re constantly
Biocom LifeLines Summer 2015
Emplo y RULEees You d ! e someserve PERK S!
Are you social? We are too!
Give Back Get involved with the Biocom Institute and give back to a veteran or future innovator. The Biocom Institute’s veteran’s initiative is focused on assisting veterans with mentoring and career assistance and providing introductions to life science companies. The San Diego Festival of Science & Engineering promotes all things STEM, getting students of all ages excited about science, technology, engineering and math. Interested in becoming a big sister or bother? We’ve partnered with Millennium Health and Big Brothers Big Sisters of San Diego County to pair Biocom members with 11 to 13 year-old girls and boys.
Never Stop Learning Whether you’re looking to move from the lab bench to a leadership position, improve your public speaking and presentation skills or, if you’re new to the industry, want to better understand the life science space, we offer professional courses at discounted rates.
looking for different ways to improve the health and happiness of our members. Biocom Concierge is an all-inclusive network of our member services, from travel to photography to 401ks. The Biocom employee perk program is designed for employees at Biocom member companies. We’ve partnered with many of your favorite San Diego businesses to bring you personal and exclusive discounts and benefits.
Employee Perks Program Who wouldn’t want to save money? We’ve partnered with many of your favorite SoCal businesses to bring personal and exclusive discounts and benefits to our members. With discounts to SeaWorld, Knott’s Berry Farm, Hyatt, barre3 UTC and much more! We are always adding new perks, check back often to discover additional benefits and savings.
Stay Healthy You’re in the business of saving lives and you need to be healthy to succeed. Biocom members receive discounts for classes at barre3, personal training at Fitness and Motion, gym memberships at the Lawrence Family Jewish Community Center and more.
We want our benefits to work for you, so we assess all our offerings regularly and adapt them to the needs of our changing industry. Keep an eye out for our new employee resource guide, which details all these perks and more, and check back often to discover additional benefits and discounts. If you have any questions, or ideas for fun new benefits we should be offering, please let me know. I can be reached at 858.455.0300 x123 or email@example.com.
Sonali Vitacchi is the Coordinator for Biocom.
OPERATIONAL EXCELLENCE. STREAMLINED SOLUTIONS. For over 160 years, VWR has been growing strong because of our unique approach to collaborating and encouraging innovation with our customers. Over time they have been challenged with finding the answers that help improve lives. Our mission is to enable this by eliminating the process complexities and identifying product and service solutions that help labs and production facilities work better, faster, and smarter. Through our global reach and knowledgeable associates, we proudly excel in delivering solutions that improve productivity, accelerate discovery, and encourage innovation.
DRIVING SUPPLY CHAIN INNOVATION
Supply Chain is more important now than ever.
Among VWR's strengths is knowledge and expertise in logistics - ensuring the right products are reaching our customers on time, every time. Our customer focused approach offers total solutions, from discovery in research and education to production, and delivering operational excellence on a global scale to: Reduce total cost of acquisition - with streamlined procurement to fill orders quickly and efficiently. Drive supply chain security - to minimize your risk. • Ensure product quality - with every order. • •
Together, VWR and Biocom combine their core strengths to offer total solutions that advance scientific innovation in the life sciences, providing you with substantial cost savings and service solutions to accelerate science from discovery to production. Extend your purchasing power by taking advantage of the power of the VWR - Biocom partnership, and realize a total solution platform, so you can focus on what's truly important: Science.
By Liisa Bozinovic, Executive Director, Biocom Institute
Volunteering to Grow and Diversify the STEM Pipeline Our industry offers many ways to give back to the community that make good business sense as well. Many Biocom member companies are already involved with patient advocacy groups. Another logical initiative is to grow and diversify the STEM pipeline. Whether you or your colleagues have a passion for explaining science to kids or helping veterans in their transition from military service, our charitable organization, the Biocom Institute, has volunteer opportunities for everyone. Check out our website at biocominstitute.org and contact us today to take advantage of these opportunities. Help Veterans Around 13 percent of San Diego’s population is military. Whether you are a veteran or interested in giving back to a veteran, we have a number of opportunities. Volunteers can develop or participate in programs to assist veterans through our Veteran Initiatives Committee or engage in one-on-one mentoring through our Veteran Career Mentoring Program. There are many ways to contribute and some that don’t require a lot of time. Even if you cannot contribute today, if you are currently working in the life science industry and are a veteran or are interested in helping veterans, we want to know who you are. We will keep you abreast of our veteran programs and events so you can participate when the time is right. Teacher Fellows Program Are you a scientist, engineer or other STEM professional? We offer ways to reach hundreds of students without ever leaving your lab or office. Because the best way to reach these students is through their chemistry, math, science and physics teachers, the Biocom Institute launched our Fellows Program. Fellows attend a major international industry conference, an industry networking mixer and best practices seminars, as well as have an opportunity to shadow you at work – running tests, designing experiments, managing projects and performing other useful tasks. Fellows are eager to take these experiences back to the classroom and share them with their students.
San Diego Festival of Science & Engineering The Festival is a great way to get out into the community and showcase your company’s science, technology or engineering expertise. As an exhibitor, you have the amazing opportunity to watch the sparkle in each kid’s eyes as they stop by your booth to participate in your activity. Exhibitor or not, we always need volunteers throughout the week, especially at Expo Day, where we see more than 24,000 kids and families at Petco Park. If you would rather be in the schools, we are also looking for professionals to visit K-12 classrooms. You don’t have to be a scientist or engineer, just passionate about your company’s mission and able to communicate to kids. Beyond School Walls STEM Program Are you interested in becoming a big sister or big brother but can’t find the time? We have partnered with Millennium Health and Big Brothers Big Sisters of San Diego County to pair Biocom member employees with 11 to 13 year old girls and boys from Innovation Middle School. During the program, which runs through the 2015/2016 school year, you meet with your little brother/sister for 90 minutes every other Wednesday, from 1:45 to 3:15 pm at our Biocom offices. The first 30 minutes will be an organized STEM program. During the remaining time, you can take advantage of the amenities around our offices, such as yoga and fitness classes, Torrey Pines State Park, basketball, board games on the patio and more to spend quality time with your little brother or sister. Help ignite the spark of enthusiasm for all of the great work being done in our local life science industry by sharing your talents and knowledge.
Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR Initiative.
Biocom LifeLines Spring 2015
By Sara Pagano, Managing Director, SD Festival of Science & Engineering
San Diego Festival of Science & Engineering – An Epic Success Nearly 90,000 STEM enthusiasts went all-in for science during the seventh annual San Diego Festival of Science & Engineering last March. For one week, San Diego County businesses, universities and professionals hosted events to showcase the business of science in Southern California and inspire K-12 students to consider STEM careers. Without the generosity of philanthropic businesses, we would not be able to continue our mission to provide opportunities for youth from all backgrounds to participate in hands-on activities, meet real scientists and engineers, and learn how recent discoveries and research affect our daily lives. Thank you 2015 San Diego Festival of Science & Engineering sponsors and partners – YOU help us spark the imaginations of future innovators and, possibly, future employees. 2015 Honor Roll • Presenting Sponsor: Illumina • Gold Sponsors: ABC10 and Aztec 15, The City of San Diego, Diversity in STEAM Magazine, Microsoft, Qualcomm, San Diego Padres and ViaSat • Silver Sponsors: Biocom Purchasing Group, CBS Radio, Cox Communications, Hologic, Inc., Reuben H. Fleet Science Center, San Diego County Office of Education, Time Warner Cable and VWR • Copper Sponsors: Ackerman Foundation, County of San Diego, Cubic Corporation, Cymer, Ferring Pharmaceuticals, Scatena Daniels Communications, Think Blue San Diego, Thermo Fisher Scientific, UTC Aerospace Systems and Vertex • Krypton Sponsors: Bank of America, Mission Federal Credit Union, Northrop Grumman, Pfizer, Inc. and Sequenom • Titanium Sponsors: AT&T, D&K Engineering, EMD Millipore, General Atomics, Kaiser Permanente, International Bridge Technologies, LEGOLAND California, Point Loma Nazarene University, San Diego National Defense Industry Association, STEM Job and Raytheon • We Love STEM Sponsors: American Elements, Canale Communications, Promo Shop, San Diego Financial Literacy Center, Thermo Fisher Scientific, UTC Aerospace Systems and Vertex • Partners: CSU San Marcos, San Diego State University, STEAM Connect and UC San Diego Think, Drink, Science – Brewing a Spark When children come to our events, their faces light up. We want
Biocom LifeLines Summer 2015
Saturday, August 15th R S V P : W W W. L O V E S T E M S D . O R G
to fuel this same spark for adults, and believe our new program –Think, Drink, Science – is a great way to start. Craft beer is a burgeoning industry in San Diego, and since our goal is to show how science and engineering are right in our backyard, this event is a great way to expose the intricate science behind beer – something many of us enjoy daily. If we can get parents hooked on STEM education, it will pave the way for students to embrace it as well. We are honored to have The Homebrewer host our inaugural event on August 15. “Beer has always found itself at the happy crossroads between science, technology, culture, and economics,” said George Thornton, owner of The Homebrewer. “Or perhaps those things have always been happy to have beer along for the ride. Countless findings about our world have been in part because of our curiosity about fermentation, alcohol and beer. Events like this are simply a continuation of this long line of fascination. You can call it evolution. We’re thrilled to be a part of this conversation and to work with such a great team.” San Diego is a hotbed for scientific innovation, offering a uniquely collaborative spirit, high concentration of world-class research institutions and a strong foundation to create and develop new companies. Our festival is a catalyst to transfer that knowledge and collaboration and show students and parents how science translates into careers and fuels our economy. Save the date for the 2016 San Diego Festival of Science & Engineering, which kicks off with EXPO Day on March 5, 2016 with an amazing Festival Week to follow. To sponsor or exhibit, visit www.lovestemsd.org.
Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering
SAN DIEGO FESTIVAL OF SCIENCE & ENGINEERING EXPO DAY: From left to right: Congresswoman Susan Davis congratulates Molly of Solana Santa Fe Elementary
School on being a recipient of the 2015 STEM Design award; The love of science is for all ages, as families engage together at EXPO Day 2015; A father-son team work together to build their molecular structure out of mini-marshmallows; Attendees at the Biocom Institute Booth talk about their STEM heroes; A spark is ignited as a future employee of Illumina has fun learning about DNA; Winners of the Bright Idea Society award, from High Tech High, teach students about Cyanotyping; An inside look at the mechanics behind D & K Engineering during Festival Week., Excitement enfolds as students have a â€œcloser lookâ€?.
Biocom LifeLines Spring 2015
MEMBERS IN ACTION BIO OVER THE YEARS: The BIO International Convention is the worldâ€™s largest, most influential biotech meeting that regularly attracts 15,000 of the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education that go far beyond professional development. San Diego has played host to the BIO International Convention three times in 2001, 2008 and 2014 and we look forward to having the Convention return on June 19-22, 2017. Biocomâ€™s participation in the Convention has been strong through the years as we showcase the Southern California life science region, despite where the convention is hosted.
Biocom LifeLines Summer 2015
MEMBERS IN ACTION
SeqCap EZ Choice Target Enrichment System
Sequence what matters Whole Genome Sequencing can be difficult. Your target enrichment choice is EZ... SeqCap EZ Choice. n
I ncrease the efficiency of targeted capture — benefit from 2.1 million overlapping probes. D iscover more variants while optimizing sequencing efficiency — multiplex up to 12 samples in a lane and achieve higher capture uniformity, minimizing your sequencing. New! Overnight hybridization protocol increases your speed to discovery.
For more information, visit www.nimblegen.com/seqcap or contact your Roche representative. For life science research only. Not for use in diagnostic procedures. NIMBLEGEN and SEQCAP are trademarks of Roche. © 2015 Roche 408-60986-0515
MEMBERS IN ACTION BIOCOM GOLF TOURNAMENT: The 4th Annual Biocom Golf
Tournament benefiting the Biocom Institute and San Diego Festival of Science & Engineering was an even bigger success than last year thanks to the engagement and support of our sponsors and golfers. It was a great day and we raised over $25,000, all of which will go directly towards supporting transitioning military veterans and STEM outreach.
THANK YOU TO OUR SPONSORS:
AER Travel Hyatt House
Office Depot Enterprise National
Biocom LifeLines Summer 2015
Charles River Veolia
Thermo Fisher Scientific VWR Catalyst
ProSci Have You Considered the Single Domain Antibody Advantage? VHH or Single Domain Antibody (sdAb) Conventional Antibody
Camelid Heavy Chain Antibody
Features & Benefits • Smallest functional antibody unit (~15 kDa) • High affinity and specificity • High solubility and stability • Cost effective large scale production • Research, diagnostic, and pharmaceutical applications
ProSci offers sdAb services from immunization to production
Order by July 31, 2015 to get 20% off! Call or visit prosci-inc.com/single-domain-antibody
Need Antibodies? Go to ProSci. • >12,000 custom antibody projects completed since 1998 • In-house labs & 150,000 ft2 of animal facilities on 27 acres • USDA licensed & NIH/OLAW assured facilities
prosci-inc.com | firstname.lastname@example.org | (858) 513 2638 © 2015 ProSci Incorporated. All rights reserved.
ProSci is an antibody focused company and a leading provider of custom antibody services and catalog antibodies worldwide.
By Rick Fultz, Managing Director, Biocom Purchasing Group
Biocom Purchasing Group: Reaching New Heights We pride ourselves on the progress we’ve made in our RFP processes, securing best-in-class products and services essential to the success of the life science industry, but it’s been a real journey getting here. Back in 2003, we were a young organization with limited resources. We leveraged the BIO association and their affiliate network to help us negotiate better terms and conditions on behalf of our members. We offered nominal value to RFP respondents through support and member engagement, and our collective contract spend was modest in our earlier stages. Despite those challenges, we conducted an office supply bid, and Office Depot retained the Biocom Purchasing Group endorsement. Strong discounts were implemented, and most of our members saw significant savings and value in the contract. Since then, we have extended the contract three times, with each new term producing an increase in contract participation, discount structures and member-only benefits and services. As of June 2014, our Office Depot contract had grown into a nationally-competitive program, attracting attention from even a few of our larger companies within our association. Our Members Wanted More – and so Did We. Last summer’s office supply RFP held significant ramifications for all parties involved. For Office Depot, it signified a potential validation of their longstanding endorsement against fervent competition and a chance to cement themselves as the clear leader in our industry. For their competition, it represented premier access to our member base and the opportunity to cause considerable shifts in market share. For our members, it symbolized the redistribution of power between buyer and seller in concessions on discounts, reporting tools and customer service programs. For the Biocom Purchasing Group, it presented a first real test to see if our “all grown up” GPO could demand and secure a contract that would compete with big pharma and fortune 500 companies. This new bid would be based solely on the cachet of our contract participation, value proposition and negotiating prowess. We were looking for a contract that would change the game, and all the major competitors were invited. We solicited volunteers from companies of all sizes within our member base. Their goal was the same as ours; bring home a contract that would compete on the global stage. Armed with committed spend, verified volume and projections, significant member investments and a robust support system, we
issued an RFP that required a level of attention usually seen from a large global customer or big pharma. We knew the responses we received would reflect how far we had come as a GPO. Despite all of their posturing, our RFP participants knew a valuable opportunity when they saw one. After all, if we were asking for the moon and the stars, we knew we had to present them with a significant opportunity for this whole thing to work. So did it? I’m happy to report that – after nine months of presentations, follow ups, deliberations and negotiations – we have ourselves a new office supply contract. Office Depot dug deep and came to the table with a globally competitive contract that was bigger, bolder, broader and better than ever before. This was a huge win for them and our members. New GPO Heights. This contract win suggests we are well on our way to becoming a world-class GPO. Together with several of our other more recent RFP recipients (UniFirst, Unisource Solutions, TransPerfect, PRNewswire, etc.), we can now offer unprecedented, globallycompetitive contracts. This is great news for our members, as they continue to gain exclusive access to game-changing programs, substantial cost savings and unique Biocom-only terms, conditions and services. With projections of more than $125 million in savings for 2015, and RFPs for lab supplies and gasses on the immediate horizon, we will continue to reach new heights as a GPO and achieve operational excellence for our member companies. If you are a current customer under the Office Depot/Biocom contract, you should already be seeing the improved prices, higher-level cost savings, reporting enhancements, increased sales support and contract customization. If you are not yet a customer and/or Biocom member, give us a call and come reach new heights with us!
Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.
Biocom LifeLines Spring 2015
PREMIUM MEMBER SPOTLIGHTS PREMIUM MEMBERS AbbVie Airgas Aldevron* Alexandria Real Estate Equities Althea Arena Pharmaceuticals Bayer Healthcare Biogen* Biomed Realty Trust Biospace BP Biofuels California Manufacturing Technology Consulting Canale Communications Celgene City National Bank COI Pharmaceuticals Conatus Pharmaceuticals
Cooley LLP Deloitte DLA Piper Eli Lilly Ernst & Young Evaluate Pharma* Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic J-Labs Jones Day KPBS KPMG* Latham & Watkins Mallinckrodt Plc
Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Office Depot Pfizer Praxair Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions VWR International Wilson Sonsini Goodrich & Rosati
* New Members from January 2015 to May 2015
www.are.com Name: Jason Moorhead Job title: Assistant Vice President, Asset Services Favorite movie: Amélie; and most recently The Imitation Game Favorite books: The Goal, Shop Class as Soulcraft Favorite quote: Gandhi: “If we could change ourselves, the tendencies in the world would also change. As a man changes his own nature, so does the attitude of the world change towards him. ... We need not wait to see what others do.” Favorite TV show: I don’t have cable TV, so don’t see much, but recently enjoyed Outlander on Netflix Favorite restaurant or meal: Simon Pearce, VT Favorite city: Paris Favorite actor/actress: Keira Knightley Favorite thing to do on the weekends: Use my Balboa Park Explorer Pass with my family What CD can we find in your car: The Jam – All Mod Cons Favorite hobby: Restoring vintage oddities (primarily Vespa & Lambretta motor scooters)
Biocom LifeLines Summer 2015
Favorite website: Craig’s List (to search for vintage oddities to restore) Favorite spot in Southern California: Secret beach spot in La Jolla First job: Lab Technician, The Salk Institute Favorite part of your job: Learning about the life-changing work being performed in the laboratories of Alexandria’s client tenants. If you could have another career, what would it be: Category 1 bicycle mechanic working the Giro d’Italia Why did you start working in your industry: I have always been intrigued by scientific discovery, and found a way to contribute to the advancement of life sciences by supporting the built environment where improvements to human health are made.
Leaders in Life Science Tenant Representation No other tenant representation firm represents more life science companies in San Diego. Below is a select listing of engagements we have completed in the last year.
55,600 SF Relocation
30,000 SF Expansion
8,400 SF Lease Renewal
29,300 SF Lease Renewal and Expansion
7,600 SF New Location
33,900 SF Relocation
30,100 SF Lease Renewal and Expansion
65,500 SF Lease Renewal and Expansion
10,200 SF Lease Renewal
65,280 SF Lease Renewal
82,500 SF Lease Renewal
13,000 SF Relocation
www.hughesmarino.com (619) 238-2111
PREMIUM MEMBER SPOTLIGHTS www.coipharma.com Your Name: Jennifer Arthur Job title: VP, Finance Favorite movie: The Great Race. Natalie Wood’s outfits were amazing, and Jack Lemon as Professor Fate was a riot! My favorite line in the movie is, ”Hit the button, Max”! Did I mention I have a son named Max? Enough said. Favorite book: The Phantom Tollbooth by Norton Juster. I loved that book as a kid and loved reading it to my four sons. Favorite quote: “The lazy man always does twice the work.” Spanish proverb. But I know it from my father, Alex Gehr, saying it to my brother and I growing up. Now I say it to my kids. Favorite TV show: The Good Wife and Parenthood Favorite restaurant or meal: My cousin Olga’s Colombian Empanadas with ají Favorite city: Encinitas Favorite actor/actress: Robert Downey Jr. / Julianna Margulies Favorite thing to do on the weekends: Along with my husband, watch and or play sports with our sons What CD can we find in your car: I don’t play CD’s in the car anymore, but my favorite Pandora stations are Thievery Corporation, Duran Duran and George Michael Favorite hobby: Running and golfing Favorite website: Amazon.com
Favorite spot in Southern California: Torrey Pines State Park First job: Working at a dry cleaners. It was here that I learned the value of hard work and teamwork. Every Saturday morning I had to arrive an hour before the store opened. My first task of the day was to wax the rails by applying car wax to the assembly line rails while standing on a milk crate. I took great pride in knowing that my efforts contributed to the overall efficiency of the dry cleaners by making the hangers fly down the assembly line. Favorite part of your job: I love the culture and energy you find working for a start-up. The people are passionate and the science innovative. At COI Pharmaceuticals, I have the unique opportunity of being a part of forming and supporting several start-ups a year. If you could have another career, what would it be: Golf Professional Why did you start working in your industry: I wanted to be able to combine my love for finance with science.
Atheln is a Contract Development Organization delivering solutions to biopharma companies Innovative virtual product development approach Multidisciplinary strategy and plans from early stage to exit Team of industry seasoned experts excel in delivering solutions for risk control Integration of technical and commercial considerations to maximize product value
PREMIUM MEMBER SPOTLIGHTS www.jonesday.com
Name: Tamera Weisser, Ph.D., J.D. Job title: Co-leader, Global Patent Prosecution Group & Partner
Name: Emad Fareed Job title: Audit Partner - KPMG’s Life Science Practice
Favorite movie: Some Like It Hot by Billy Wilder Favorite books: To Kill a Mockingbird by Harper Lee Favorite quote: “Be the change that you wish to see in the world.” - Mahatma Ghandi Favorite TV show: House of Cards, Scandal, The Good Wife Favorite restaurant or meal: Mama Mia’s in Milwaukee, WI Favorite city: Paris, France Favorite actor/actress: Cary Grant / Katherine Hepburn Favorite thing to do on the weekends: Spend time with my husband and son. What CD can we find in your car: Joe Dirt Car by the BoDeans Favorite hobby: Cooking and gardening Favorite website: Facebook and LinkedIn Favorite spot in Southern California: My home First job: Vendette selling popcorn at a movie theater Favorite part of your job: Interacting with our clients and digging into the science behind their inventions to help provide a strategic business plan to company management. If you could have another career, what would it be: Something in the film industry. Why did you start working in your industry: I was a research scientist for almost 10 years in both academic and industry settings, which gave me an appreciation for the business side of science. I was able to parlay that experience into my legal career as an IP attorney representing primarily biotech and pharmaceutical company clients.
Favorite movie: The Godfather, Something about Mary Favorite books: The Alchemist, The Catcher in the Rye Favorite quote: “All that we are is the result of all that we have thought.” - Buddha Favorite TV show: Deadliest Catch Favorite restaurant or meal: Italian Favorite city: New York (it’s where I grew up). Favorite actor/actress: Leonardo DiCaprio, Al Pacino Favorite thing to do on the weekends: Go swimming with my kids, anything outdoors What CD can we find in your car: I don’t have CD’s but have a wide music taste that ranges from current top hits to hip hop. Anything but country. Favorite hobby: Fishing, playing any sport Favorite website: www.nytimes.com, www.espn.com Favorite spot in Southern California: Almost any beach, the beaches are beautiful here! First job: Tennis instructor for kids 3 to 15 – it was a great experience! I also was a golf caddy. Favorite part of your job: My life science clients deliver an important service to society. I enjoy helping my clients succeed through difficult issues so they can be most effective. If you could have another career, what would it be: Golf caddy for the PGA tour. Why did you start working in your industry: What drew me to public accounting and KPMG is the great sense of camaraderie and purpose behind the work performed. I really enjoy working with clients in the life sciences industry that are in different stages of their life cycle (from start-up, pre-revenue companies to commercially successful public companies).
BIOCOM SPOTLIGHT Name: Shaye Exner Job title: Senior Director of Corporate Sponsorship Favorite movie: Rudy Favorite books: Who has time to read with 2 kids! The last book I read was called “Toddlers are !@#$holes” I enjoyed it immensely Favorite TV show: Childhood: Family Ties College: Felicity (still love it actually) My 20’s: Um SATC obvi Recent: Mad Men, Game of Thrones, Breaking Bad & Friday Night Lights (Coach Taylor I love you!) Oh and the Vampire Diaries but I will never admit that in public. Oops. Favorite restaurant or meal: Best meal I have had in the last 12 months was at AVEC in Chicago. Amazing chorizo stuff dates! Favorite city: New York City or Chicago, I go where the food is. Favorite actor/actress: this changes all the time, but currently I like Oscar Isaac and Rosemarie DeWitt
Favorite thing to do on the weekends: Take my kids to the zoo or the park. Watching them play together (nicely) make me the happiest. That and drinking lots of wine. What CD can we find in your car: Do people still have CD’s in their car? Favorite hobby: Listening to Podcasts. Obsessed right now. Check out “The Moment with Brian Koppleman” or “Here’s the Thing” and obviously “This American Life” Favorite website: Facebook Favorite spot in Southern California: Disneyland First job: Concession Stand at the local movie theater Favorite part of your job: Closing a deal If you could have another career, what would it be: Psychologist
Biocom LifeLines Spring 2015
BOARD OF DIRECTORS BOARD OFFICERS AND EXECUTIVE COMMITTEE: CHAIR: Theodore Schroeder* VICE CHAIR: Carin Canale-Theakston, Canale Communications* CHAIR ELECT: Daniel Burgess* VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* CHAIR EMERITUS: Magda Marquet, Ph.D., Althea (A member of the Ajinomoto Group)* PRESIDENT & CEO: Joe Panetta, Biocom* Vincent Anido, Ph.D., Aerie Pharmaceuticals Steven Bartz, Ph.D., Merck & Company Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Michael Boyd, AbbVie Michael Brown, Stradling Yocca Carlson & Rauth Terrance J. Bruggeman John M. Dunn Stephen Ferruolo, J.D., Ph.D., USD School of Law* M. Wainwright Fishburn, Jr., Cooley LLP* Don Fitzgerald, Genentech Jack Florio Gregory Fond, Sanofi Global R&D Gregory Frost, Intrexon Corp. Carol Gallagher Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Jason Hannon, NuVasive Richard Heyman, Ph.D. Elliot Hirshman, Ph.D., San Diego State University Matthew Hudes, Deloitte LLP Guy J. Iannuzzi, Mentus Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation David Kabakoff, Ph.D., Sofinnova Ventures Steve Kaldor, Ph.D., Quanticel Katherine Kantardjieff, Ph.D., California State University San Marcos Paul Laikind, Ph.D., ViaCyte Jacob Levin, Ph.D., UC Irvine James Levine, Sapphire Energy* Jack Lief, Arena Pharmaceuticals, Inc.* John Lister, Dexcom Damien McDevitt, Ph.D., GlaxoSmithKline
Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* William Molloie, PwC Tracy Murphy, Biomed Realty Trust Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.* Perry Nisen, M.D., Ph.D., Sanford-Burnham Medical Research Institute Brian O’Callaghan Kenneth Polin, Jones Day Trindl Reeves, Barney & Barney LLC* Gregory Reyes, M.D., Ph.D., Celgene Dan Ryan, Alexandria Real Estate Equities Camille Saltman, Malama Composites, Inc. James Schaeffer, Ph.D., Calibr* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek* Bhasker Shetty, Ph.D., Pfizer La Jolla Larry Stambaugh, Kalos Therapeutics* Mark Stevenson, Thermo Fisher Scientific* Tsuneo Takahashi, NF Corporation Scott N. Wolfe, Latham & Watkins LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects* David Hale, Hale BioPharma Ventures* Tina Nova, Ph.D., Ilumina Biocom Board Members-Ex-Officio: Sandra Brown, Ph.D., UCSD Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Scott Lippman, MD, Moores Cancer Center, UCSD Greg McKee, CONNECT Peter Preuss, The Preuss Foundation Jerry Sanders, San Diego Regional Chamber of Commerce David Webb, Ph.D., Scripps Research Institute *Executive Committee Member
COMMITTEE LEADERSHIP BIG DATA George Bonaros, Biocom Biocom Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield
Biocom LifeLines Summer 2015
FDA Committee Magda Marquet, Ph.D.,Althea (A member of the Ajinomoto Group) Michele Yelmene, Pharmalink Consulting Intellectual Property and Patent Law Committee Daniel Hart, Knobbe Martens Olson & Bear LLP Michael Mueller, Conatus Pharmaceuticals International Committee Kenneth Polin, Jones Day Legislative Committee Richard Ledford April Grant, Sunovion Pharmaceuticals Medical Device Committee Mike Oliver, Spectra Science Joleen Schultz, Rady School of Management, UCSD
Digital Health Committee Kira Jenkins, Biocom Public Policy Oversight Committee* Larry Stambaugh, Kalos Therapeutics Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Scholarship Committee Bente Hansen, BenteHansen and Associates Veterans Committee Josh Vosovic *Board Level Committees
BIOCOM MEMBERSHIP PREMIUM
BP Biofuels California Manufacturing Technology Consulting Canale Communications Celgene City National Bank COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper
Eli Lilly Ernst & Young Evaluate Pharma* Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic J-Labs Jones Day
KPBS KPMG* Latham & Watkins Mallinckrodt Plc Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Office Depot
Pfizer Praxair Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions VWR International Wilson Sonsini Goodrich & Rosati
Cell Applications Celladon Cellana Center for Aquaculture Technologies Chubu Technology Licensing Office Cibus Cidara Therapeutics Coda Therapeutics Conju-Probe Contract Biotics Cosmederm Bioscience* Crinetics Pharmaceuticals Cypher Genomics Dart Neuroscience Definiens Diomics Corporation DNA Link USA* DNAtrix DSM Food Specialties E&B Technologies Edico Genome* eFFECTOR Therapeutics Elcelyx Therapeutics Electronic BioSciences eMolecules Epeius Biotechnologies Equitech Bio Eton Bioscience Fabrus Fate Therapeutics Forge Therapeutics* Formex Genelux Corporation Genentech Genlantis Genoa Pharmaceuticals Genomatica Genovo Corporation GenSignia Life Sciences GigaGen GlaxoSmithKline Global Medical & Research Technologies Guangdong Consun Pharmaceutical Company GWR Instruments Halozyme Therapeutics Histogen Human Longevity Huya Bioscience International
IDEXX BioResearch Illumina Imprimis Pharmaceuticals Inception Sciences Indi Molecular* Inhibrx InnoPep Innovative Cell Technologies Innovus Pharmaceuticals* Inovio Pharmaceuticals Integrated DNA Technologies Intercept Pharmaceuticals International Stem Cell Intrepid Therapeutics Intrexon Corporation Intrinsic LifeSciences Invetech InvivoGen IRBCo. ISIS Pharmaceuticals J-Oil Mills JSR Micro Kalos Therapeutics Kalyra Pharmaceuticals Koltan Pharmaceuticals Kura Oncology Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Lpath Lumena Pharmaceuticals MabVax Therapeutics Malama Composites Mast Therapeutics MDRejuvena* MEI Pharma Meiji Seika Pharma* Meritage Pharma Mirati Therapeutics Monsanto MultiVir Nautilus Environmental Neothetics NeuroGenetic Pharmaceuticals NF Techno Commerce Nitto Denko Technical Novartis Pharmaceuticals Novo Nordisk Nucelis
OBI Pharma USA* Ocera Therapeutics Ohr Pharmaceuticals Optimum Therapeutics Orexigen Therapeutics OrPro Therapeutics Otonomy Pacira Pharmaceuticals Panmira Pharmaceuticals Patara Pharma Pathway Genomics PersImmune Pfenex PharmAkea Polaris Group Polynoma PolyPeptide Group Poseida Therapeutics* Predictive Biology PrimaPharm PrimeGen Biotech Primordial Genetics Prognosys Biosciences ProSci QED Bioscience Qingdao Ming Yaotang Medical Technology Qingdao Newsummit New Drug Public Service R&D Platform Quanticel Pharmaceuticals Receptos Regulus Therapeutics REKA Health Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies Ridgeline Engineering Roche Applied Science Rohto Pharmaceutical RQX Pharmaceuticals RuiYi Sapphire Energy Samumed Samsara Sciences Sanofi Sciencescape Scripps Laboratories Senior Scientific* Senju USA Senomyx
SentĂŠ Seragon Pharmaceuticals SGB Silicon Biosystems Sirenas Marine Discovery Solstice Biologics SomaLogic Sophiris Bio Sorrento Therapeutics SOVA Pharmaceuticals Sparsha Pharma USA* Stemedica Cell Technologies StemImmune* Sunovion Pharmaceuticals SynteractHCR Synthetic Genomics Takeda Pharmaceuticals U.S.A. Tanabe Research Laboratories TEGA Therapeutics Tenova Pharmaceuticals Thesan Pharmaceuticals Tocagen Tonbo Biosciences TP Therapeutics Tracon Pharmaceuticals Tragara Pharmaceuticals Triphase Accelerator Triton Health & Nutrition* UCB US Specialty Labs Vantari Genetics Vaxiion Therapeutics Verdezyne Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Viking Therapeutics Visionary Pharmaceuticals Vital Therapies Wellspring Biosciences Wildcat Discovery Technologies World Fusion US Xencor Xycrobe Therapeutics Zogenix
AbbVie Airgas Aldevron* Alexandria Real Estate Equities Althea Arena Pharmaceuticals Bayer Healthcare Biogen* Biomed Realty Trust Biospace
Abcore Abgent Abide Therapeutics Abilita Bio* Abwiz Bio ACADIA Pharmaceuticals ActivX Biosciences Advanced BioMatrix Advanced Targeting Systems Aerie Pharmaceuticals Afraxis Agena Bioscience Ajinomoto Pharmaceuticals* AM Chemicals AMBRX Ambryx Biotechnology Amgen Amicrobe Amplyx Pharmaceuticals AnaptysBio AndroScience Ansun Biopharma Apricus Biosciences Arcturus Therapeutics Ardea Biosciences Arrayomics Arytha Biosciences* Astellas Pharma aTyr Pharma Auspex Pharmaceuticals Avantgen Avelas Avidity NanoMedicines Aviva Biosciences Bachem Americas BASF BioLegend Biomatrica Biomyx BioNano Genomics Bionomics Bio Options BioSpyder Technologies BioWa Boehringer-Ingelheim Curtana Pharmaceuticals CalciMedica CannaVest Corporation
* New Members from January 2015 to May 2015
Biocom LifeLines Spring 2015
BIOCOM MEMBERSHIP CRO/CMO
Atheln Beaufort CRO Behavioral Pharma Bend Research BioAgilytix Labs BioAtla Bioserv Corporation BTS Research CalChem Synthesis Cassia Cato Research Charles River Laboratories ChemDiv Combi-Blocks Concortis Biosystems Crown Bioscience San Diego* Cytelligen Davos Chemical DD Studio
Drug Delivery Experts Epistem eStudySite Exon BioSystems Expertise Engineering Explora BioLabs GENEWIZ GRAM Laboratories Hamari Chemical San Diego Research Center HD Biosciences Huntingdon Life Sciences IMS Health Integrium Clinical Research Interplex Sunbelt inVentive Health Clinical IriSys iXCells Biotechnologies USA* JadeBio
LCMS Solutions Mediconomics MicroConstants Molecular Response MPI Research My Chem LLC Neuroservice Neuro-Sys Outerspace Design Group* PacificGMP PharPoint Research PharmaDirections* Pharmatek Laboratories Profil Institute For Clinical Research PSI CRO Puracyp Quadrants Scientific Reveal Biosciences Rho
Robarts Clinical Trials Roowin SAFC Pharma Sherpa Clinical Packaging Spaulding Clinical Research Starfish Medical Therapeutics, Inc. Tioga Research Toxikon Triligent International Ultimate Labs Verum.us VIRAPUR Wax-It Histology Services WuXi AppTec Zensun USA Zyagen
MEDIC AL DEVICE & DIAGNOSTIC
CeloNova BioSciences Celula Cliniqa Corporation ClinMet CombiMatrix* Compellon Critical Diagnostics Cure Care CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom Diagnostic Consulting Network Dorsa Vi USA Ellipse Technologies Emerge Diagnostics Endologix Enigma Diagnostics Entra Health Systems Epic Sciences
Epitope Diagnostics Fallbrook Engineering FemCap Fortimedix USA Freedom Meditech GenomeDx Biosciences* GenWay Biotech GIMDx* Glaukos Corporation Glysens Hitachi Chemical Research Center Hygeia Medical Ichor Medical Systems Ignyta ImpediMed ImThera Medical Inari Medical Inceptus Medical INOVA Diagnostics Interpreta Interventional Spine
InVision Biomedical Group Invivoscribe Technologies Ionian Technologies Ivantis Ivera Medical KFx Medical MARDX Diagnostics Medipacs Micell Technologies Millennium Health Nano Imaging Services Nanomedical Diagnostics NuFACE Omniome OncoSec Medical Organovo Parallel 6 Pediatric Bioscience Prometheus Laboratories Qualigen Quidel
Quinn Medical ReShape Medical REVA Medical ReVision Optics Roka Bioscience Sequenom Sequent Medical Shire Sienna Labs Sirigen Sonendo SpectraScience Spinal Elements* Suneva Medical Tandem Diabetes Targeson TherOx Tristan Technologies Trovagene Uptake Medical Yulex
Institute Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute Kaiser Permanente La Jolla Bioengineering Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center Los Angeles Biomedical Research Institute Medicon Valley Alliance MiraCosta College Biotech Program Mt. San Jacinto College PhRMA Point Loma Nazarene University Rady School of Management, UCSD Salk Institute For Biological Studies
San Diego Biomedical Research Institute San Diego Blood Bank San Diego Clinical and Translational Research Institute, UCSD San Diego Community College District San Diego Employers Association San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp. San Diego Supercomputer Center (UCSD) San Diego Workforce Partnership Sanford-Burnham Medical Research Institute Scottish Development International Scripps Health Scripps Research Institute
Swedish American Chamber Of Commerce San Diego The BioIndustry Association The Lowy Medical Research Institute (LMRI) Torrey Pines Institute for Molecular Studies UC San Diego Extension UCIâ€™s Office of Research UCSD, Department of Bioengineering UCSD, Health Systems- Center for Occupational & Environmental Medicine UCSD, Office of Advancement UCSD School of Medicine UCSD, Technology Transfer Office UK Trade & Investment University of San Diego
3DT Holdings* Abbiotec ABL* Absorption Systems Accelagen Accugent Laboratories Acurian Advantar Laboratories Agility Clinical Alliance Protein Laboratories A&M Biomedical* Ambit Biosciences American Peptide Company AnaBios Animantis Annova Chem ARIANNE
Acon Laboratories Aethlon Medical Alphatec Spine AltheaDx Amydis Diagnostics* Applied Proteomics Astute Medical Axonics Modulation Technologies Banyan Biomarkers BeneChill Biocept BioDx Biological Dynamics Biomerica bioTheranostics Breathe Technologies Bruin Biometrics Cell Idx
American Cancer Society, Border Sierra Region Battelle CA Institute for Regenerative Medicine Calibr California Baptist University, College of Engineering California Medical Innovations Institute California State University, San Marcos Case Western Reserve, School of Engineering* City Of Murietta CONNECT Consulate Of Canada CSU,CSUPERB Program Human BioMolecular Research
Biocom LifeLines Summer 2015
Antoinette Azevedo Bernard King Carol Gallagher Donna Janson Elliot Parks Gary Friedman John Dunn John Kavanagh Julie Ames Peter Preuss Richard Ledford Stan Kim*
KEY PROVIDER Barney & Barney Cushman & Wakefield Oracle Health Sciences Qualcomm San Diego Gas & Electric
2Connect Accelrys ADVI AER Travel AIS Data Centers Alexander’s Mobility Services Alliant Insurance* AMN Healthcare Assay Depot Bank of America Beckloff Associates Bench International Bente Hansen & Associates Berkshire Hathaway Home Services Bionest Partners BioSurplus Biotech Primer Biotech Vending BioTix Blue Sky Broadcast Bootstrap Incubation
Brizzey* Caliber Associates California Commercial Security Cambridge Research Biochemicals Canteen Vending Services CBRE Central Pharma Contract Packaging* China Business Partners Chubb Group of Insurance Companies Clinigen Healthcare Coastal Payroll Services* Controlled Contamination Services Corning Covisint Corporation Cox Business Cymer Domain Associates EBD Group Elsevier Enterey EquipNet Euretos Exp U.S. Services Ferguson Pape Baldwin Architects Fisher & Phillips Forward Ventures Fragomen, Del Rey, Bernsen & Loewy French Biobeach Frequentz Gable PR Gensler
Grande Colonial Green Charge Networks* Gunderson Dettmer* Hartl Team- Private Banking & Investment Group- Merrill Lynch Haworth HCP Life Science Estates H.G. Fenton Company Hyatt Regency La Jolla at Aventine IBM Life Sciences Innovative Lease Services Intersection* J.T. MacMillan Photography Jackson & Blanc HVAC Contractors Jones Lang LaSalle Kilroy Realty Knobbe, Martens, Olson & Bear Leadership Edge Legacy Partners Commercial Life Science IT* Lonza AG Managed Laboratory Services Managed Solution Mayer Hoffman McCann McKenna Long & Aldridge Medidata Solutions Medline Industries Mehlman Barnes Mercury Fund Morgan, Lewis & Bockius Morrison & Foerster
Newhoff Healthcare Communications* Occupational Services Orion International Patent Office Oxford Finance Pharmalink Consulting Pharmour* PR Newswire Prevost Construction Procopio, Cory, Hargreaves & Savitch Project Management Advisors Retirement DNA San Diego World Trade Center Sartorius SecureDocs Scient Federal Credit Union Sharp Business Systems Sheppard Mullin Richter & Hampton Shred San Diego Signature Analytics Silicon Valley Bank Sofinnova Ventures Sonceboz Corporation Speid & Associates* Square 1 Bank S Squared Executive Search Stradling Yocca Carlson & Rauth Savills Studley Sughrue Mion Surplus Solutions* Technical Safety Services The Business Cleaning Company
The HealthEd Group The Sandler Group Thomas, Mcnerney & Partners Time Warner Cable Unanet* Unifirst United Parcel Service (UPS) Vault Bioventures* VDP Direct Veolia WCCT Global
* New Members from January 2015 to May 2015
Legal Counsel to the Life Sciences Industry • Formation and Organization
• Intellectual Property
Don Pelto, Partner email@example.com | 202.747.1911
• Clinical Trials • FDA Regulatory • Healthcare Regulatory
Lorna Tanner, Partner
firstname.lastname@example.org | 650.815.2658
• Labor and Employment • Real Estate • Litigation
Beijing | Brussels | Century City | Chicago | Del Mar | London | Los Angeles | New York Orange County | Palo Alto | San Diego | San Francisco | Seoul | Shanghai | Washington, D.C. www.sheppardmullin.com
10996 Torreyana Rd, Suite 200 San Diego, CA 92121-3021 www.Biocom.org Please send a change of address or subscription request to Sonali Vittachi at svittachi@Biocom.org.
Microbial Fermentation Workshop
August 12-14, 2015 | 8:00 a.m. – 5:00 p.m. UC San Diego Campus, La Jolla, CA
This 3-day workshop, developed in partnership between UC San Diego’s Center for Continuing Education in Biosciences (CCE|BIO) and UC San Diego Extension, is designed to provide a deep dive into bioreactor operations for microbial fermentations and equip you with the knowledge and practical skills needed to optimize your processes. Designed for professionals with fundamental experience in fermentation, this program will facilitate the exploration of bioprocess simulation, economics and modern techniques used in applying process analytical technology in manufacturing. • Apply biological principles to problems involving microbial growth systems • Comprehend modern techniques used in applying process analytical technology in manufacturing • Examine bioreactor operations in microbial cell systems and the scale-up of bioreactors
For more information and to register: (858) 534-9353 | email@example.com extension.ucsd.edu/lifesciences
SPEAKERS: JAMES GOLDEN, PH.D., Professor, UC San Diego MICHAEL FINO, M.ENG., Faculty, MiraCosta College JEFF LIEVENSE, PH.D., Senior Engineering Fellow, Genomatica JON HANSEN, PH.D., Sr. Technical Director, DSM TIM DODGE, PH.D., Sr. Staff Scientist, Dupont MICHAEL JAPS, Process Development Engineer, Genomatica
Fermentor Demos by DCI-Biolafitte
Published on Aug 21, 2017